申请人:SHILPA MEDICARE LIMITED
公开号:US20170107193A1
公开(公告)日:2017-04-20
The present invention relates to process for the preparation of highly pure Lenalidomide (I).
The invention also relates to crystalline Form-SL obtained by the process of the present invention., the said Form-SL being substantially pure and characterized by X-ray powder diffraction pattern comprising of at least seven peaks selected from 7.061, 12.860, 16.531, 18.698, 27.925, 33.212, 34.187, 35.253, 35.921 and 38.765±0.1°2θ; a single un-split °2θ peak at 7.813±-.1°2θ; and a three-way split °2θ peak at 20.467±0.1°2θ.
The invention further relates to pharmaceutical compositions comprising crystalline Form-SL of Lenalidomide, which may be useful for the treatment of cancer.
本发明涉及一种制备高纯度Lenalidomide(I)的过程。本发明还涉及通过该过程获得的结晶形式SL,所述形式SL具有X射线粉末衍射图谱,包括至少从7.061、12.860、16.531、18.698、27.925、33.212、34.187、35.253、35.921和38.765±0.1°2θ中选择的七个峰;一个单一未分裂的7.813±-.1°2θ峰;以及一个三分裂的20.467±0.1°2θ峰,所述形式SL基本纯净。本发明还涉及包含Lenalidomide结晶形式SL的制药组合物,可用于癌症治疗。